BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
To Evaluate Effectiveness of Visanne in Improving Quality of Life in Asian Women With Endometriosis
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 895
- Registration Number
- NCT02425462
Duration of Use of Highly Effective Reversible Contraception
Completed
- Conditions
- Pregnancy
- Interventions
- First Posted Date
- 2015-04-13
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 13880
- Registration Number
- NCT02414919
Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 278
- Registration Number
- NCT02413515
Risk Minimisation Study for Diane-35 and Its Generics
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Drug: Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 759
- Registration Number
- NCT02410031
Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1471
- Registration Number
- NCT02403401
Regorafenib Phase I Study in Mainland Chinese Patients
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18
- Registration Number
- NCT02398513
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
Completed
- Conditions
- Castration-Resistant Prostatic Cancer
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 363
- Registration Number
- NCT02398526
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
Phase 3
Completed
- Conditions
- Glaucoma, Neovascular
- Interventions
- Drug: Sham Injection
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 54
- Registration Number
- NCT02396316
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Completed
- Conditions
- Hemophilia A
- Interventions
- Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 272
- Registration Number
- NCT02396862
To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.
Phase 1
Completed
- Conditions
- Pharmacology, Clinical
- Interventions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT02394093
© Copyright 2025. All Rights Reserved by MedPath